MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
Autolus Therapeutics plc DIO Ratio 2011-2026 | AUTL
Annual DIO Ratio Autolus Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 70.7 | 66.3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70.7 | 66.3 | 68.5 |
Quarterly DIO Ratio Autolus Therapeutics plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.3 | 72 | 37.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82.3 | 37.2 | 63.9 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K |  USA |
 |
AbbVie
ABBV
|
91.6 | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
ANI Pharmaceuticals
ANIP
|
181 | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Cocrystal Pharma
COCP
|
60.5 | $ 1.51 | 48.04 % | $ 17 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
BioMarin Pharmaceutical
BMRN
|
644 | $ 55.5 | -3.04 % | $ 10.6 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
46.7 | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Amgen
AMGN
|
200 | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
474 | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Bristol-Myers Squibb Company
BMY
|
68.7 | $ 59.6 | -2.45 % | $ 121 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
892 | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cellectis S.A.
CLLS
|
23.3 | $ 3.41 | 1.19 % | $ 116 M |  France |
 |
Biogen
BIIB
|
351 | $ 177.34 | -3.5 % | $ 26 B | USA |
 |
Axon Enterprise
AXON
|
116 | $ 412.81 | -2.54 % | $ 31.3 B | USA |